| 2-AG | 2-arachidonoylglycerol |
| AEA | N-arachidonoyl ethanolamide |
| CB1R | Cannabinoid receptor type 1 |
| CB2R | Cannabinoid receptor type 2 |
| FDA | Food & Drug Administration |
| NSAIDs | Nonsteroidal anti-inflammatory drugs |
| Δ9-THC | Δ9-Tetrahydrocannabinol |
| Δ9-THCA | Δ9-tetrahydrocannabinolic acid |
| Δ9-THCV | Δ9-tetrahydrocannabivarin |
| AM251 | N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide |
| AM281 | N-(morpholin-4-yl)-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxamide |
| AM630 | 6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone |
| AM1241 | (2-iodo-5-nitrophenyl)-[1-(1-methylpiperidin-2-ylmethyl)-1H-indol-3-yl]-methanone |
| AT | Anandamide transporter |
| ACPA | Arachidonylcyclopropylamide |
| Aβ | Beta-amyloid |
| CB | Cannabinoid |
| CBD | Cannabidiol |
| CBDL | Cannabinodiol |
| CBC | Cannabichromene |
| CBCV | Cannabichromevarin |
| CBL | Cannabicyclol |
| CBE | Cannabielson |
| CBG | Cannabigerol |
| CBGV | Cannabigerovarin |
| CBGM | Cannabigerol Monoethyl Ether |
| CBN | Cannabinol |
| CBT | Cannabitriol |
| CBV | Cannabivarin |
| COX2 | cyclooxygenase subtype 2 |
| CP55940 | (−)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol |
| ERK | Extracellular-regulated kinase |
| FAAH | Fatty acid amide hydrolase |
| GI | Gastrointestinal |
| GCPR | G-Coupled Protein Receptor |
| HU-210 | (6aR)-trans-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol |
| JWH-015 | (2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone |
| JWH-133 | 3-(1,1-dimethylbutyl)-6,6,9-trimethyl-6α,7,10,10α-tetrahydro-6H-benzo[c]chromene |
| PPARγ | Peroxisome proliferator-activated receptor γ |
| TRVP1 | Transient receptor potential vanilloid type 1 |
| MAP | Mitogen-activated protein kinase |
| R-(+)-WIN55212 | (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone |
| SR141716A | N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride |
| SR144528 | N-[(1S)-endo-1,3,3-trimethyl bicyclo [2.2.1] heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-carboxamide |
| DAGL | Diacylglycerol lipase |
| MAGL | Monoacylglycerol lipase |
| NAPE-PLD | N-acetyl-phosphatidyl-ethanolamine-hydrolyzing phospholipase D |
| PEA | Palmitoylethanolamide |
| OEA | Oleoylethanolamine |
| FAAH | Fatty acid amide hydrolase |
| NAAH | N-acylethanolamine acid amide hydrolase |
| ABHD6 | Alpha/beta-Hydrolase domain containing 6 |
| ABHD12 | Alpha/beta-Hydrolase domain containing 12 |
| GABA | Gamma aminobutyric acid |
| GPR55 | G-protein coupled receptor 55 |
| GPR18 | G-protein coupled receptor 18 |
| GPR119 | G-protein coupled receptor 119 |
| FABS | Fatty Acid Binding Protein |
| HSP70s | 70 kilodalton heat shock proteins |
| AMT | Anandamide membrane transporter |
| EMT | Endocannabinoid membrane transporter |